tamayra 5 mg/5 mg tvrdé kapsuly
swyssi ag, nemecko - ramipril a amlodipín - 58 - hypotensiva
telhycar 80 mg/25 mg tablety
swyssi ag, nemecko - telmisartan a diuretiká - 58 - hypotensiva
telhycar 80 mg/12,5 mg tablety
swyssi ag, nemecko - telmisartan a diuretiká - 58 - hypotensiva
bilastin stada 20 mg tablety
stada arzneimittel ag, nemecko - bilastín - 24 - antihistaminica, histamin
oxynal 40 mg/20 mg
stada arzneimittel ag, nemecko - oxykodón a naloxón - 65 - analgetica - anodyna
oxynal 30 mg/15 mg
stada arzneimittel ag, nemecko - oxykodón a naloxón - 65 - analgetica - anodyna
oxynal 20 mg/10 mg
stada arzneimittel ag, nemecko - oxykodón a naloxón - 65 - analgetica - anodyna
oxynal 10 mg/5 mg
stada arzneimittel ag, nemecko - oxykodón a naloxón - 65 - analgetica - anodyna
oxynal 5 mg/2,5 mg
stada arzneimittel ag, nemecko - oxykodón a naloxón - 65 - analgetica - anodyna
clopidogrel acino
acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotické činidlá - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.